Cybin Inc. - CYBN STOCK NEWS

Cybin Inc. has announced that its subsidiary, Adelia Therapeutics, has successfully achieved milestones outlined in a December 2020 agreement. This includes the issuance of 31,721.5 Class B common shares worth approximately $628,879.34 to Adelia shareholders at an effective price of $1.98 per share. These Class B shares are exchangeable for Cybin shares at a ratio of 10 to 1, with specific exchange conditions. Cybin continues to advance its mission to develop therapeutics addressing mental health issues through innovative drug delivery systems.

Cybin, a biopharmaceutical company, has announced a grant for the establishment of a pioneering psychedelic treatment clinic at Lenox Hill Hospital in New York. This initiative will focus on aiding marginalized communities by offering treatment at no out-of-pocket cost. The clinic aims to provide psychedelic therapies for severe mental health conditions and frontline workers affected by COVID-19. Clinicians will be trained in various psychedelic-assisted psychotherapies, underlining the potential of these modalities in treating previously intractable conditions like depression and PTSD.

Cybin Inc. reported its unaudited financial results for the second quarter ended September 30, 2021. The company holds C$75.2 million in cash, but recorded a net loss of C$17.6 million. Cybin is advancing its CYB003 program, aiming for an investigational new drug application submission in Q2 2022 for treating depression and addiction. Recent highlights include a Schedule I manufacturing license, FDA approval for a feasibility study with Kernel Flow technology, and the launch of the EMBARK program for frontline workers.

Cybin, a biopharmaceutical company focused on advancing Psychedelics to Therapeutics, announced that CEO Doug Drysdale will present at the Jefferies London Healthcare Conference from November 18-19, 2021. The presentation will be available on demand starting November 18 at 8:00 AM GMT until November 19 at 5:00 PM GMT. Investors can access the webcast through Cybin's website. Founded in 2019 and headquartered in Canada, Cybin collaborates with leading partners to develop therapeutics for mental health issues.

Cybin Inc. (NYSE American:CYBN) will report its financial results for Q2 fiscal 2021, ending September 30, 2021, on November 15, 2021. A conference call to discuss results will occur on the same day at 4:30 p.m. EST, hosted by CEO Doug Drysdale. The company is dedicated to developing safe and effective psychedelic therapeutics for mental health. Cybin operates in Canada, the U.S., the UK, and Ireland, leveraging advanced drug discovery and delivery systems.

Cybin Inc. (AMEX:CYBN) has been granted a Schedule I manufacturing license by the U.S. Drug Enforcement Agency (DEA) for its Boston area research lab. This license allows the company to enhance its internal research and development capabilities for studying Schedule I controlled substances, marking a significant progression in their clinical and regulatory efforts. Additionally, Leah Gibson has been appointed as the new Vice President of Investor Relations, bringing over 18 years of experience in the life sciences sector. Former Chief Business Officer John Kanakis will transition to focus on M&A and business development.

Cybin Inc. (AMEX:CYBN) announces a research and development briefing scheduled for November 8, 2021, from 8:30 AM to 9:30 AM EST in Miami. The event will unveil positive pre-clinical research findings regarding the psilocybin molecule as a potential therapeutic for mental health issues. Cybin emphasizes its commitment to creating effective and safe treatment options amidst a growing mental health crisis exacerbated by COVID-19. The briefing will feature key insights from the company’s leadership and include a Q&A session for attendees.

Cybin Inc. (AMEX:CYBN) has launched the EMBARK Psychedelic Facilitator Training Program aimed at preparing clinical trial facilitators to ethically support participants receiving psychedelic treatment. The program, in collaboration with the University of Washington, includes an in-person training retreat and is set to kick off this fall. The initial cohort will prepare for a clinical trial investigating psilocybin-assisted psychotherapy for healthcare workers facing COVID-related distress. EMBARK employs a transdiagnostic model to address various therapeutic needs, emphasizing a holistic approach to healing.

Cybin has received FDA authorization for an Investigational New Drug (IND) application to conduct a feasibility study measuring ketamine's psychedelic effects using Kernel’s Flow technology. This innovative neuroimaging technology allows for the dynamic tracing of brain activity during psychedelic experiences, representing a significant advancement in psychedelic therapeutics. The study aims to gather real-time quantitative data, potentially enhancing the understanding of psychedelic treatments for psychiatric disorders. Cybin retains exclusive rights to any innovations derived from the study.